Article Information
History
- August 24, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- David Hodgson1,*,
- Mihaly Koltai1,
- Fabienne Krauer1,
- Stefan Flasche1,
- Mark Jit1 and
- Katherine E. Atkins1,2
- 1Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK
- 2Centre for Global Health, Usher Institute, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK
- ↵*Corresponding author Email: david.hodgson{at}lshtm.ac.uk
Posted August 24, 2022.
Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales
